Can BAC tests detect chronic alcohol use
Ancona A, Petito C, Iavarone I, Petito V, Galasso L, Leonetti A et al (2021) The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease
The highest tirzepatide dose group achieved an average weight loss of more than 20% in that trial
Stepping up to 3% or 5% is an option for thicker skin, stubborn areas, or patients who've plateaued, but higher concentrations carry more irritation risk
Lilly said in June that its orforglipron candidate achieved a near-15% weight loss after 36 weeks in a mid-stage trial, while Novo Nordisk has said it is preparing to file an oral semaglutide formulation for obesity later this year, and also has early-stage results for a next-generation candidate called amycretin
Theres no strong bitterness or lingering aftertaste, either. Of her overall experience, Courtney liked that it was a low-maintenance supplement that fit in well with her lifestyle